New service partnership
VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use...
August 12, 2021
CF models for drug development
HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids™ advance treatment for...
August 5, 2021
Test epithelial barrier function
Discover the development of a new model to assess drug safety, absorption, methabolism, transport, and permeability. Compromised intestinal barrier function has been...
July 14, 2021
HUB Organoids at Innovation Parade
HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the Innovation Parade, an online event organized by the Embassy of the Kingdom of The...
April 26, 2021
HUB and Yamaha for IVD
April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today continuation of their collaboration to provide...
May 27, 2020
Ovarian cancer organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer...
May 13, 2020
Understanding gut’s hormones
Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species of animals....
May 1, 2020
SARS-CoV-2 infects gut cells
Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have found that...
April 1, 2020
A message from our CEO on COVID-19
Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. These are...
February 21, 2020
Organoids for genetic disorders
Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest CRISPR technology...
